SEATTLE--(BUSINESS WIRE)--MitoPharm Corporation, Inc. (Pinksheets:MTPM), announced today the results of Dr Robert Ko’s, MitoPharm CTO, most recent study, which together with the previous findings on long-term schisandrin B treatment, suggests that schisandrin B can precondition heart cells, and most likely brain cells too, making them more resistant to stress conditions such as heart attack and stroke.
